Japan is rapidly establishing itself as a global center for AI innovation by building across the full technology stack with NVIDIA hardware and software. This week, NVIDIA and its Japanese partners are showcasing breakthroughs in healthcare, life sciences, and industrial automation that signal AI has moved beyond pilot projects into mission-critical operations.

How Are Japanese Pharmaceutical Companies Using AI for Drug Discovery?

Japan's leading pharmaceutical firms have united around AI-powered drug discovery platforms, with Tokyo-1, an AI drug discovery consortium operated by Xeureka, expanding to include major companies like Eisai, Astellas, Daiichi Sankyo, and Ono Pharmaceuticals. These organizations are deploying NVIDIA BioNeMo, a specialized AI framework designed for life sciences research.

The practical applications are concrete and measurable. Astellas has deployed nearly all BioNeMo microservices within NVIDIA's digital biology portfolio and is running BioNeMo Agent Toolkit, an open platform that turns AI agents into autonomous life sciences researchers. Ono Pharmaceuticals is using the Boltz-2 microservice to streamline internal drug discovery workflows. Daiichi Sankyo is conducting ultralarge-scale virtual screening on Tokyo-1 and leveraging NVIDIA RAPIDS, a data processing framework, to accelerate large-scale computational analysis.

Two emerging companies are advancing molecular AI capabilities. SyntheticGestalt announced two products: ZAO, a molecular AI foundation model that converts small molecules into data AI can process through a "4D" representation capturing multiple 3D molecular conformations, and KOYA, a molecular generative model that designs novel ligands for target proteins. ZAO ranked number one on nine public drug-discovery benchmark tasks, achieving world-class performance. Both products integrate with NVIDIA BioNeMo Agent Toolkit, enabling AI agents to evaluate and design molecules collaboratively with researchers.

Biomy is pioneering a virtual cell foundation model using a massive clinical dataset from the Japanese Foundation for Cancer Research. Using NVIDIA single-cell RAPIDS, Biomy achieved 90 percent faster spatial transcriptomics analysis, a critical capability for understanding cellular behavior in drug development. Biomy will use NVIDIA Nemotron-powered agents to autonomously propose and orchestrate complex virtual experiments.

What Role Are Surgical Robots Playing in Japanese Hospitals?

Physical AI, the integration of AI reasoning with robotic systems, is entering the operating room. Kawasaki Heavy Industries, a major Japanese manufacturer, is developing surgical support functions, nursing assistant, and hospital transport robots using NVIDIA Holoscan IGX, Isaac for Healthcare, Isaac GR00T, and Cosmos technologies. These tools enable robots to understand surgical environments and assist medical teams in real time.

Direava is developing a surgical vision language model for real-time surgical video understanding and natural language interaction with surgical scenes. This technology aims to evolve into an intelligence layer for future surgical AI systems in the operating room, allowing AI to understand what surgeons are doing and provide contextual assistance.

How Are Medical Imaging Companies Integrating NVIDIA Hardware?

Two of Japan's leading medical imaging manufacturers are now shipping next-generation computed tomography (CT) systems built on NVIDIA GPUs. Canon launched Japan's first NVIDIA-accelerated photon-counting CT system, a significant advancement in imaging technology. Fujifilm has commercialized Japan's first whole-body CT system powered by NVIDIA Blackwell, the company's latest GPU architecture, using diffusion-based deep learning reconstruction to improve image quality.

The integration of AI and accelerated computing into medical imaging equipment contributes to improved image quality, enhanced diagnostic accuracy, early disease detection, and higher standards of medical care. Together, these advances signal a fundamental shift: AI is no longer an experiment in Japanese healthcare but has become core infrastructure.

Ways NVIDIA Metropolis Is Accelerating Vision AI Development

• Comprehensive Skill Library: NVIDIA Metropolis now packages more than 80 new skills, including NVIDIA VSS Blueprint 3.2, NVIDIA DeepStream 9.1, NVIDIA TAO 7, and Physical AI Data Factory, helping developers use coding agents to speed development by at least 6 times compared to traditional methods.
• Real-Time Video Analytics: NVIDIA DeepStream 9.1 helps developers create and deploy real-time, multi-sensor video analytics pipelines from edge to cloud for large-scale ingestion, multi-camera tracking, and operations analytics across distributed systems.
• Model Customization and Optimization: NVIDIA TAO 7 helps developers customize and optimize NVIDIA Cosmos and other vision AI models with agent skills for labeling, performance diagnostics, fine-tuning, data generation, and automated machine learning workflows.
• Synthetic Data Generation: NVIDIA Physical AI Data Factory skills help developers use NVIDIA Cosmos to automatically generate and augment synthetic image and video data to fill training gaps for rare or new product defects, environmental changes, and other edge cases.

Japan's industrial and smart-space leaders including Asilla, AWL, Fujitsu, Hitachi, OMRON, Shimizu Corporation, and Yazaki North America are using Metropolis to bring vision AI agents into factories, construction sites, stores, buildings, and public spaces. These deployments demonstrate how agentic vision systems can understand, reason, and act on real-world video data in real time.

The broader significance of these developments extends beyond individual companies. Japan's ecosystem of manufacturers, robotics pioneers, infrastructure builders, and technology companies is collectively demonstrating how to build AI systems across the full technology stack, from hardware accelerators to specialized software frameworks to domain-specific applications. This integrated approach positions Japan as a model for how mature industrial economies can adopt AI not as a peripheral tool but as foundational infrastructure across healthcare, manufacturing, and logistics.